RM Bio‑Tech Secures CDE Approval for HF001 Stem‑Cell Therapy in Type 2 Diabetes
Beijing RM Bio‑Tech Co., Ltd. announced that the Center for Drug Evaluation (CDE) under the...
Jiangsu Hengrui’s Adebrelimab New Indication Accepted by NMPA for Stage II‑IIIB NSCLC
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) announced that the National Medical Products...
Yantai Dongcheng Secures NMPA Approval for 225Ac‑LNC1011 Alpha‑Particle Radiopharmaceutical to Target Prostate Cancer
China‑based Yantai Dongcheng Pharmaceutical Group Co., Ltd. (SHE: 002675) announced that its investigational 225Ac‑LNC1011 injection...
Eli Lilly Announces $6.5 B Houston Facility to Boost Synthetic‑Medicine API Production
Eli Lilly (NYSE: LLY) announced today that it will construct a new $6.5 billion manufacturing complex...
Sino Biopharmaceutical Reports First‑Patient Enrollment for LM‑2417 Phase I Trial
China‑based Sino Biopharmaceutical (HKG: 1177) announced today that its internally‑developed Class 1 innovative drug LM‑2417 has...
MSD Teams with Variational AI in $349 Million Generative‑AI Drug Discovery Deal
Merck, Sharp & Dohme Inc. (MSD; NYSE: MRK) has struck a $349 million partnership with Canada‑based...
ProBio and Immunofoco Forge Global CGT Manufacturing Alliance
ProBio, a subsidiary of GenScript Biotech Corporation (HKG: 1548), and China‑based Immunofoco have inked a...
Stealth BioTherapeutics Receives FDA Accelerated Approval for Forzinity in Barth Syndrome
The U.S. Food and Drug Administration (FDA) granted accelerated approval to Stealth BioTherapeutics’ Forzinity (elamipretide)...
China Drug Procurement: Centralized Rules Shape 11th Round Of VBP
The Joint Procurement Office of the National Healthcare Security Administration (NHSA) published the definitive rules...
Genrix Bio Secures Exclusive Deal for Vecantoxatug and Silevimig with CMS
China‑based Chongqing Genrix Bio Pharmaceutical Co., Ltd. (SHA: 688443) and China Medical System Holdings Ltd....
Roche’s SC Lunsumio Gains CHMP Recommendation for Relapsed Follicular Lymphoma
Roche (SWX: ROG, OTCMKTS: RHHBY) announced that the European Medicines Agency’s Committee for Medicinal Products...
Roche’s giredestrant Yields Positive PFS Results in evERA Phase III Study
Roche (SWX: ROG, OTCMKTS: RHHBY) announced that its Phase III evERA trial has met both co‑primary...
Shanghai Sanyou Medical’s Agloe Robot Enters Chinese NMPA Special Review for Innovative Spine Devices
Shanghai Sanyou Medical Co., Ltd. (SHA: 688085) announced that its affiliate Agloe Medical Technologies has...
Eisai Secures FDA Fast Track for Etalanetug, a Tau Antibody Targeting MTBR
Eisai Co. Ltd. (TYO: 4523) announced today that its investigational tau‑protein antibody etalanetug (E2814) has...
Pfizer to Acquire Metsera for $4.9 B, Expanding Its Obesity & Cardiometabolic Pipeline
Pfizer Inc. (NYSE: PFE) announced today that it will acquire Metsera, Inc. (NASDAQ: MTSR), a...
Youcare Pharma Secures FDA Approval for YKYY013, a Novel siRNA Therapy for Chronic Hepatitis B
Youcare Pharmaceutical Group (SHA: 688658) announced that the U.S. Food and Drug Administration (FDA) has...
National Healthcare Security Administration Announces Nationwide Pilot for Real‑World Medical‑Insurance Value Evaluation
The National Healthcare Security Administration (NHSA) today issued a notice outlining a multi‑city pilot program...
Huadong Medicine Secures FDA IND Approval for HDM2017 ADC
Huadong Medicine Co., Ltd. (SHE: 000963) announced today that the U.S. Food and Drug Administration...
Sichuan Kelun‑Biotech’s A400 Receives NDA Acceptance in China
Sichuan Kelun‑Biotech Biopharmaceutical Co., Ltd. (HKG: 6990) announced today that the Center for Drug Evaluation...
Visen Pharmaceuticals Secures Hainan Approval for Palopegteriparatide
Visen Pharmaceuticals (HKG: 2561) announced today that its innovative drug palopegteriparatide (TransCon PTH) has received official...